Form 4: Anixa Biosciences President, COO, & CFO Michael Catelani Reports Transaction
SEC Form 4 Filing
Michael Catelani, President, COO, & CFO of Anixa Biosciences, reports a transaction involving the company's common stock on January 15, 2025.
Summary
- On January 15, 2025, Michael Catelani, the President, COO, and CFO of Anixa Biosciences, engaged in a transaction involving the company's common stock.
- Catelani acquired 9,289 shares of common stock at a price of $2.15 per share.
- Following the reported transaction, Catelani beneficially owns 44,500 shares of Anixa Biosciences.
Sentiment
Score: 5
Explanation: This is a neutral report of an insider transaction. The sentiment is neither positive nor negative without additional context.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC when a company insider, like the President, COO, & CFO, engages in a transaction involving the company's securities. It provides transparency to the market regarding insider activity.
Stakeholder Impact
- The transaction may have a minor impact on shareholders as it provides insight into the actions of a key executive.
Key Dates
| Date | Description |
|---|---|
| 01/15/2025 | Date of transaction: Michael Catelani acquired 9,289 shares of Anixa Biosciences common stock. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.